Background: Genetic and developmental disruption of surfactant protein B (SP-B) expression causes neonatal respiratory distress syndrome (RDS).
Objectives: To assess developmental and genetic regulation of SP-B expression in vivo.
Methods: To evaluate in vivo developmental regulation of SP-B, we used immunoblotting to compare frequency of detection of mature and pro-SP-B peptides in developmentally distinct cohorts: 24 amniotic fluid samples, unfractionated tracheal aspirates from 101 infants >or=34 weeks' gestation with (75) and without (26) neonatal RDS, and 6 nonsmoking adults. To examine genetic regulation, we used univariate and logistic regression analyses to detect associations between common SP-B (SFTPB) genotypes and SP-B peptides in the neonatal RDS cohort.
Results: We found pro-SP-B peptides in 24/24 amniotic fluid samples and in 100/101 tracheal aspirates from newborn infants but none in bronchoalveolar lavage from normal adults (0/6) (p < 0.001). We detected an association (p = 0.0011) between pro-SP-B peptides (M(r) 40 and 42 kDa) and genotype of a nonsynonymous single nucleotide polymorphism at genomic position 1580 that regulates amino-terminus glycosylation.
Conclusions: Pro-SP-B peptides are more common in developmentally less mature humans. Association of genotype at genomic position 1580 with pro-SP-B peptides (M(r) 40 and 42 kDa) suggests genetic regulation of amino terminus glycosylation in vivo.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2765709 | PMC |
| http://dx.doi.org/10.1159/000153095 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Developmental and genetic regulation of human surfactant protein B in vivo.
Neonatology
May 2009
Division of Newborn Medicine, the Edward Mallinckrodt Department of Pediatrics and St. Louis Children's Hospital, St. Louis, Mo. 63110, USA.
Background: Genetic and developmental disruption of surfactant protein B (SP-B) expression causes neonatal respiratory distress syndrome (RDS).
Objectives: To assess developmental and genetic regulation of SP-B expression in vivo.
Methods: To evaluate in vivo developmental regulation of SP-B, we used immunoblotting to compare frequency of detection of mature and pro-SP-B peptides in developmentally distinct cohorts: 24 amniotic fluid samples, unfractionated tracheal aspirates from 101 infants >or=34 weeks' gestation with (75) and without (26) neonatal RDS, and 6 nonsmoking adults.
Expression profiles of hydrophobic surfactant proteins in children with diffuse chronic lung disease.
Respir Res
July 2005
Kinderklinik and Poliklinik, Dr. von Haunersches Kinderspital, Ludwig-Maximilians University, Munich, Germany.
Article Synopsis
- The study investigates the role of hydrophobic surfactant proteins SP-B and SP-C in chronic childhood lung diseases, particularly focusing on children with pulmonary alveolar proteinosis (PAP) and other respiratory issues.
- Researchers analyzed bronchoalveolar lavage fluid to compare the presence of these proteins in diseased children against those without lung issues, finding certain protein forms linked to specific genetic mutations.
- The findings suggest that testing for these surfactant protein abnormalities can provide insights into pediatric lung disorders, showcasing a minimally invasive diagnostic approach.
Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis.
Am J Pathol
May 2005
Department of Anesthesiology Critical Care Medicine, Childrens Hospital Los Angeles, California, USA.
The hallmark of idiopathic pulmonary fibrosis (IPF) is the myofibroblast, the cellular origin of which in the lung is unknown. We hypothesized that alveolar epithelial cells (AECs) may serve as a source of myofibroblasts through epithelial-mesenchymal transition (EMT). Effects of chronic exposure to transforming growth factor (TGF)-beta1 on the phenotype of isolated rat AECs in primary culture and a rat type II cell line (RLE-6TN) were evaluated.
View Article and Find Full Text PDFProcessing of pulmonary surfactant protein B by napsin and cathepsin H.
J Biol Chem
April 2004
Cancer Center Karolinska, Department of Oncology-Pathology, Karolinska Institute and Hospital, SE-171 76 Stockholm, Sweden.
Surfactant protein B (SP-B) is an essential constituent of pulmonary surfactant. SP-B is synthesized in alveolar type II cells as a preproprotein and processed to the mature peptide by the cleavage of NH2- and COOH-terminal peptides. An aspartyl protease has been suggested to cleave the NH2-terminal propeptide resulting in a 25-kDa intermediate.
View Article and Find Full Text PDFInduced p21Cip1 in premature baboons with CLD: implications for alveolar hypoplasia.
Am J Physiol Lung Cell Mol Physiol
October 2003
Dept. of Pediatrics, Box 850, Univ. of Rochester, 601 Elm-wood Ave., Rochester, NY 14642, USA.
Aberrant pulmonary epithelial and mesenchymal cell proliferation occurs when newborns are treated with oxygen and ventilation to mitigate chronic lung disease. Because the cyclin-dependent kinase inhibitor p21 inhibits proliferation of oxygen-exposed cells, its expression was investigated in premature baboons delivered at 125 days (67% of term) and treated with oxygen and ventilation pro re nata (PRN) for 2, 6, 14, and 21 days. Approximately 5% of all cells expressed p21 during normal lung development of which <1% of these cells were pro-surfactant protein (SP)-B-positive epithelial cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!